Trials / Completed
CompletedNCT01077258
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,208 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.
Detailed description
Patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented. The follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.
Conditions
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2010-03-01
- Last updated
- 2014-04-25
- Results posted
- 2014-04-08
Locations
303 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01077258. Inclusion in this directory is not an endorsement.